148 related articles for article (PubMed ID: 38575189)
1. Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses.
Ruwanpathirana GP; Williams RC; Masters CL; Rowe CC; Johnston LA; Davey CE
J Nucl Med; 2024 May; 65(5):781-787. PubMed ID: 38575189
[TBL] [Abstract][Full Text] [Related]
2. Inter-scanner Aβ-PET harmonization using barrel phantom spatial resolution matching.
Ruwanpathirana GP; Williams RC; Masters CL; Rowe CC; Johnston LA; Davey CE
Alzheimers Dement (Amst); 2024; 16(1):e12561. PubMed ID: 38476638
[TBL] [Abstract][Full Text] [Related]
3. β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3.
Bourgeat P; Doré V; Burnham SC; Benzinger T; Tosun D; Li S; Goyal M; LaMontagne P; Jin L; Rowe CC; Weiner MW; Morris JC; Masters CL; Fripp J; Villemagne VL;
Neuroimage; 2022 Nov; 262():119527. PubMed ID: 35917917
[TBL] [Abstract][Full Text] [Related]
4. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
[TBL] [Abstract][Full Text] [Related]
5. Implementing the centiloid transformation for
Bourgeat P; Doré V; Fripp J; Ames D; Masters CL; Salvado O; Villemagne VL; Rowe CC;
Neuroimage; 2018 Dec; 183():387-393. PubMed ID: 30130643
[TBL] [Abstract][Full Text] [Related]
6. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal head-to-head comparison of
Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ;
JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
[TBL] [Abstract][Full Text] [Related]
9. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
Landau SM; Lu M; Joshi AD; Pontecorvo M; Mintun MA; Trojanowski JQ; Shaw LM; Jagust WJ;
Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396
[TBL] [Abstract][Full Text] [Related]
10. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.
Asken BM; Elahi FM; La Joie R; Strom A; Staffaroni AM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Karydas A; Wang P; Rojas JC; Boxer AL; Miller BL; Rabinovici GD; Kramer JH; Casaletto KB
J Alzheimers Dis; 2020; 78(1):265-276. PubMed ID: 32986672
[TBL] [Abstract][Full Text] [Related]
11. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
[TBL] [Abstract][Full Text] [Related]
12. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
13. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
15. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
16. Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET.
Guo T; Brendel M; Grimmer T; Rominger A; Yakushev I;
J Nucl Med; 2017 Apr; 58(4):639-645. PubMed ID: 27754901
[TBL] [Abstract][Full Text] [Related]
17. Spatial Normalization of
Lilja J; Leuzy A; Chiotis K; Savitcheva I; Sörensen J; Nordberg A
J Nucl Med; 2019 Feb; 60(2):285-291. PubMed ID: 29903930
[TBL] [Abstract][Full Text] [Related]
18. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
20. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ;
J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
